Martin Auster
Stock Analyst
(1.28)
# 4,648
Out of 4,648 analysts
47
Total ratings
50%
Success rate
2.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $66.01 | +81.79% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $51.06 | +105.64% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $3.26 | +697.55% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $5.66 | +2,020.14% | 4 | Mar 16, 2021 | |
| GLTO Galecto | Maintains: Outperform | $725 → $300 | $6.73 | +4,357.65% | 2 | Mar 16, 2021 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $49 → $58 | $13.10 | +342.75% | 3 | Mar 10, 2021 | |
| UTHR United Therapeutics | Maintains: Outperform | $169 → $196 | $376.80 | -47.98% | 4 | Feb 22, 2021 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | $62 → $98 | $1.49 | +6,477.18% | 2 | Feb 11, 2021 | |
| INSM Insmed | Maintains: Outperform | $50 → $60 | $68.09 | -11.88% | 2 | Jan 19, 2021 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | $65 | $27.67 | +134.91% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $123.07 | -40.68% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $2.71 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $5.56 | +1,302.88% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.00 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $17.81 | +141.44% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $44.82 | -24.14% | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $15.14 | +38.71% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $19.94 | -19.76% | 1 | May 7, 2020 |
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $66.01
Upside: +81.79%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $51.06
Upside: +105.64%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $3.26
Upside: +697.55%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $5.66
Upside: +2,020.14%
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $6.73
Upside: +4,357.65%
Stoke Therapeutics
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $13.10
Upside: +342.75%
United Therapeutics
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $376.80
Upside: -47.98%
ALX Oncology Holdings
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $1.49
Upside: +6,477.18%
Insmed
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $68.09
Upside: -11.88%
Scholar Rock Holding
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $27.67
Upside: +134.91%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $123.07
Upside: -40.68%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $2.71
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $5.56
Upside: +1,302.88%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $2.00
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $17.81
Upside: +141.44%
Jul 7, 2020
Initiates: Outperform
Price Target: $34
Current: $44.82
Upside: -24.14%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $15.14
Upside: +38.71%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $19.94
Upside: -19.76%